Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Archived Press Releases

Keyword Search
 
Recent News Releases | Archived News Releases
DateTitle 
05/31/16Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
PARSIPPANY, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2016 Healthcare Conference at 9 a.m. ET on Tuesday, June 7, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the compan... 
Printer Friendly Version
05/03/16Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PARSIPPANY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” ... 
Printer Friendly Version
05/02/16Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
-- Total Net Revenues Up 12 Percent Year-Over-Year -- -- EXPAREL® Net Revenues Up 14 Percent Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., May 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2016. “With immense leverage across our or... 
Printer Friendly Version
04/19/16Pacira Pharmaceuticals Appoints Charles A. Reinhart III as Chief Financial Officer
PARSIPPANY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Charles A. Reinhart III to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently P... 
Printer Friendly Version
04/14/16Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., April 14, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2016 will be released before the market opens on Monday, May 2, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Monday, May 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-5... 
Printer Friendly Version
04/05/16Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
PARSIPPANY, N.J., April 05, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr. Weiland will be responsible for oversight of the commercial activities for EXPAREL® (bupivacaine liposome injectable suspension), which include marketing, sales, national accounts, training and commercial operations and analytics. Mr. Weiland will report to Jim Scibetta, President and Chief Financial O... 
Printer Friendly Version
03/08/16Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 08, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the co... 
Printer Friendly Version
03/01/16New Analysis Shows Use of EXPAREL Reduces Length of Hospital Stay and Improves Discharge Status Compared to Standard Analgesic Modality in Total Knee Arthroplasty
Data Presented at the Annual Meeting of the American Academy of Orthopaedic Surgeons PARSIPPANY, N.J., March 01, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results of new data showing that EXPAREL® (bupivacaine liposome injectable suspension) infiltration compared to a standard analgesic regimen in patients undergoing total knee arthroplasty (TKA) significantly decreased the length of hospital stay and increased the likelihood that a patient would be d... 
Printer Friendly Version
02/25/16Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
-- 2015 Total Net Revenues Up 26 Percent Over 2014 -- -- 2015 EXPAREL® Net Revenues Up 27 Percent Over 2014 -- -- Per-Protocol Analysis of Oral Surgery Data Demonstrates Statistical Significance; Supports Launch Activities in Late Third Quarter 2016 --   -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain i... 
Printer Friendly Version
02/11/16Pacira Pharmaceuticals Announces Timing for 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2015 will be released before the market opens on Thursday, February 25, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, February 25, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-84... 
Printer Friendly Version
01/07/16Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million
PARSIPPANY, N.J., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced estimated EXPAREL® (bupivacaine liposome injectable suspension) and total revenues for the fourth quarter and full-year 2015.  These estimates, which are unaudited, are based on management’s preliminary financial analysis. “We are pleased with the strong finish to 2015 and the preliminary revenues that benefited from a solid fourth quarter—seasonally the strongest period of the yea... 
Printer Friendly Version
12/28/15Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Dec. 28, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 4 p.m. PT (7 p.m. ET) on Monday, January 11, 2016, in San Francisco. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors &... 
Printer Friendly Version
12/15/15Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
-- Terms Include Labeling Changes to Reinforce that the Use of EXPAREL is not Limited to Pivotal Trial Surgical Models, and Formal FDA Rescission of 2014 Warning Letter – -- Conference Call Today at 8:30 am EST – PARSIPPANY, N.J., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has achieved an amicable resolution with the United States in its lawsuit filed on September 8, 2015, Pacira Pharmaceuticals, Inc. et al v. United States Food &am... 
Printer Friendly Version
11/24/15Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET on Tuesday, December 1, in New York City. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” ... 
Printer Friendly Version
11/17/15New Survey Sheds Light on Prescription Drug Use Among Women After Surgery in the United States
Pacira and HealthyWomen Launch ‘Voice Your Choice’ Campaign Urging Patients to Know and Discuss Their Pain Control Options Before Surgery PARSIPPANY, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- One in every 15 patients who receive prescription painkillers (also called opioids or narcotics) following surgery ends up using these medications long-term,1,2 which can result in tolerance, dependence and addiction. According to a new national survey, a lack of doctor-patient communication about postsurg... 
Printer Friendly Version
11/11/15Pacira Pharmaceuticals, Inc. to Present at the Jefferies Autumn 2015 Global Healthcare Conference
PARSIPPANY, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, president and chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies Autumn 2015 Global Healthcare Conference at 2:40 p.m. GMT (9:40 a.m. ET) on Thursday, November 19, in London. Mr. Scibetta is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Inve... 
Printer Friendly Version
11/06/15New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
Data Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons PARSIPPANY, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced positive data on the use of EXPAREL® (bupivacaine liposome injectable suspension) as a postsurgical analgesic following total knee replacement surgery. The study, which compared the use of EXPAREL infiltration to the standard of care in 1,110 patients, found that EXPAREL was associated with sign... 
Printer Friendly Version
10/27/15Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
-- Total Revenues of $62.2 Million in Third Quarter -- -- EXPAREL® Net Revenues of $59.7 Million in Third Quarter -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) --  Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2015. “Third quarter EXPAR... 
Printer Friendly Version
10/20/15Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President
-- Dave Stack Remains Chairman and Chief Executive Officer; Continues to Drive Commercial Strategy and Clinical Development of EXPAREL® and the DepoFoam® Pipeline -- -- Mr. Scibetta to Lead Tactical Execution of Operations -- PARSIPPANY, N.J., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that James S. Scibetta has been appointed president, effective October 20, 2015. In this capacity, Mr. Scibetta will oversee the day-to-day operations and ta... 
Printer Friendly Version
10/13/15Pacira Pharmaceuticals Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (PCRX) today announced that financial results for the company’s third quarter ended September 30, 2015 will be released before the market opens on Tuesday, October 27, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, October 27, 2015, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1... 
Printer Friendly Version
09/08/15Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL® Consistent with its FDA-Approved Indication
Complaint Challenges FDA’s Unlawful Efforts to Retroactively Restrict the Promotion of EXPAREL Despite Its Broad Indication PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today filed a lawsuit against the U.S. Food and Drug Administration (FDA) seeking to exercise its lawful rights to communicate truthful and non-misleading information about its flagship product, EXPAREL® (bupivacaine liposome ... 
Printer Friendly Version
08/19/15Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 19, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of James B. Jones, MD, PharmD, to the position of senior vice president and chief medical officer. Dr. Jones brings more than 25 years of experience as both a practicing and teaching physician and as a senior executive at biotechnology and pharmaceutical companies, where he led the clinical development of multiple novel pa... 
Printer Friendly Version
08/03/15Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 3, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the following investor conferences in August: Wedbush 2015 Life Sciences Management Access Conference at 8:00 a.m. ET in New York on Tuesday, August 11, 2015. ... 
Printer Friendly Version
07/30/15Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 30, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2015. “We recorded $57 million in EXPAREL product revenues in the second quarter, an increase o... 
Printer Friendly Version
07/15/15Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 15, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana Therapeutics, Inc. (NASDAQ: PETX) shared positive results from its pivotal field effectiveness study of AT-003, the company’s bupivacaine liposome injectable suspension licensed from Pacira, for managing postsurgical pain in dogs. The randomized, blinded, multicenter pivotal study in dogs undergoing knee surger... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development. Dr. Braunstein brings over 20 years of knowledge and experience from his time both as a practicing physician and investor, as well as expertise from numerous commercial, consulting and operational roles advi... 
Printer Friendly Version
07/14/15Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 14, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2015 will be released before the market opens on Thursday, July 30, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 30, 2015, at 9 a.m. ET. The call can be acc... 
Printer Friendly Version
05/28/15Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 28, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it completed an End-of-Review process with the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for the use of EXPAREL® (bupivacaine liposome injectable suspension) for administration as a nerve block to provide postsurgical analgesia. Pacira requested an End-of-Review meeti... 
Printer Friendly Version
05/20/15Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 20, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the following investor conferences in June: Jefferies 2015 Global Healthcare Conference at 11:30 a.m. ET in New York on Monday, June 1, 2015. Goldman ... 
Printer Friendly Version
05/19/15Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 19, 2015-- Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced data from three studies evaluating the clinical and pharmacoeconomic utility of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain control in patients undergoing colorectal surgery, breast reconstruction and total knee replacement surgery. The data were presented this month at the annual meetings of the World Congress of ... 
Printer Friendly Version
05/07/15Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 7, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2015 Health Care Conference at 8:40 a.m. PT on Thursday, May 14, 2015, in Las Vegas. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
04/30/15Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results
EXPAREL® Net Sales up 63% from Prior Year Period Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 30, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2015. “With just a two percent... 
Printer Friendly Version
04/16/15Pacira Receives Subpoena from the U.S. Department of Justice
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 16, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to the product EXPAREL® (bupivacaine liposome injectable suspension). Pacira intends to cooperate with the ... 
Printer Friendly Version
04/13/15Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 13, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2015 will be released before the market opens on Thursday, April 30, 2015. The Pacira management team will also host a conference call to discuss the company’s financial results and recent and upcoming developments at 9 a.m. ET on Thursday, April 30, 2015. The call can ... 
Printer Friendly Version
04/10/15Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 10, 2015-- Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced results of new data from the University of Illinois College of Medicine analyzing the impact of EXPAREL® (bupivacaine liposome injectable suspension) used to manage postsurgical pain following total knee replacement surgery. The data found EXPAREL use associated with improved clinical outcomes and a favorable cost savings per patient compared to ... 
Printer Friendly Version
03/26/15Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
-- Results Presented at the 2015 Annual Meeting of the American Academy of Orthopedic Surgeons Find Overall Hospital Cost Savings of More Than $1.5 Million -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 26, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating the benefits associated with the use of EXPAREL® (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patient... 
Printer Friendly Version
03/23/15New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures
Data Presented at the 2015 Annual Meeting of the International Anesthesia Research Society PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 23, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results of two data presentations on the impact of EXPAREL® (bupivacaine liposome injectable suspension) on postsurgical opioid requirements in patients undergoing hysterectomy or mastectomy. The data were presented during two poster sessi... 
Printer Friendly Version
03/04/15Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 4, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 3:50 p.m. ET on Wednesday, March 11, in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by ... 
Printer Friendly Version
03/02/15Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 2, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following a review of its supplemental New Drug Application (sNDA) for the use of EXPAREL® (bupivacaine liposome injectable suspension) in nerve block to provide postsurgical analgesia. Pacira will immediately schedule an End-of-Review meeting ... 
Printer Friendly Version
02/24/15Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 24, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the fourth quarter and full year ended December 31, 2014. “We believe 2014 marked another impress... 
Printer Friendly Version
02/11/15Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA’s Office of Prescription Drug Promotion
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 11, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced resolution of matters pertaining to certain promotional aspects of EXPAREL detailed in a recent Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP). Pacira announced receipt of the Warning Letter on September 25, 2014 and has since been in constructive discussions with OPDP. ... 
Printer Friendly Version
02/10/15Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 10, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2014, will be released before the market opens on Tuesday, February 24, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, February 24, 2015, at 9 a.m. ET.... 
Printer Friendly Version
01/08/15Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL® and total revenue estimates for the fourth quarter and full-year 2014. “We are pleased with the continued success of EXPAREL in the fourth quarter, growth over the previous quarter and growth for the year, which we expect to provide the basis of a strong 2015,” said Dave Stack, president, chief executiv... 
Printer Friendly Version
01/08/15Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has scheduled an Analyst & Investor Day on Thursday, Jan. 22, 2015, from approximately 4:00 to 6:30 p.m. ET in New York. Members of the Pacira management team, along with clinical experts, will provide an overview of the Company’s future expansion plans for additional EXPAREL® indications, as well as the leading DepoFoam®-based... 
Printer Friendly Version
12/12/14Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label
PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 12, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration’s (FDA) approval of changes to the EXPAREL packaging and label proposed by the Company as part of a routine label supplement application, submitted on November 27, 2013. The approved label changes are limited to revisions pertaining to the product’s storage, instructions of use and use in special popu... 
Printer Friendly Version
11/25/14Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira... 
Printer Friendly Version
11/11/14Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 11, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2014 Global London Healthcare Conference at 10:40 a.m. GMT (5:40 a.m. ET) on Wednesday, Nov. 19, 2014, in London. Mr. Stack is expected to present an overview of the company. A live audio webc... 
Printer Friendly Version
11/06/14Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
-- Data Presented at the 2014 Annual Meeting of the American Association of Hip and Knee Surgeons Finds Lower Patient-Perceived Pain Scores, Reduced Opioid Consumption and Improved Patient Satisfaction in Patients Who Received EXPAREL – PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 6, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study designed to evaluate the difference in p... 
Printer Friendly Version
10/30/14Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 30, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014. “The third quarter marked another period of consisten... 
Printer Friendly Version
10/27/14New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
--Data from American College of Surgeons Demonstrates Reduced Incidence of Respiratory Depression, Urinary Retention and Fall Risk in Patients Receiving EXPAREL-- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complicat... 
Printer Friendly Version
10/15/14Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, October 30, 2014, at 9 a.m. ET. The call... 
Printer Friendly Version
10/13/14Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block
-- Analysis Presented at the 2014 Annual Meeting of the American Society of Anesthesiologists Finds the Safety of EXPAREL Similar to Placebo and Bupivacaine HCl -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 13, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating that EXPAREL® (bupivacaine liposome injectable suspension) used in peripheral nerve blocks has comparable safety to placebo and bupivacaine HCl. T... 
Printer Friendly Version
09/25/14Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter
PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension). “We take regulatory compliance very seriously and believe that our ... 
Printer Friendly Version
08/05/14Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014, at 8:35 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
07/31/14Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First Quarter
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2014. “With nine quarters now under our belt, we are pleased wi... 
Printer Friendly Version
07/17/14Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 17, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2014, will be released before the market opens on Thursday, July 31, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, July 31, 2014, at 9 a.m. ET. The call can be ac... 
Printer Friendly Version
06/26/14Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
-- Multi-study Analysis Published in Journal of Pain Research Reinforces Value of EXPAREL-Based Multimodal Analgesia Regimen -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 26, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies designed to compare postsurgical narcotic use and health economic outcomes associated with EXPAREL® (bup... 
Printer Friendly Version
05/27/14Pacira Pharmaceuticals, Inc. to Present at June Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at investor conferences during June. Mr. Stack will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014, at 11 a.m. ET in New York. ... 
Printer Friendly Version
05/07/14Pacira Pharmaceuticals, Inc. Announces sNDA Submission for EXPAREL Nerve Block Indication
Expected PDUFA Date of March 5, 2015 PARSIPPANY, N.J.--(BUSINESS WIRE)--May 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a nerve block indication for EXPAREL® (bupivacaine liposome injectable suspension). The sNDA is based on positive data from a Phase 3 study assessing the safety and efficacy of EXPAR... 
Printer Friendly Version
05/05/14Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014, at 8 a.m. PT in Las Vegas. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Paci... 
Printer Friendly Version
05/01/14Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenue of $34.4 Million and First Quarter 2014 Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--May 1, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2014. “We are excited by the continued success of EXPA... 
Printer Friendly Version
04/17/14Pacira Pharmaceuticals Announces Timing for First Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company’s first quarter ended March 31, 2014, will be released before the market opens on Thursday, May 1, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, May 1, 2014, at 9 a.m. ET. The call can be acces... 
Printer Friendly Version
04/15/14Pacira Pharmaceuticals Announces Grants of Inducement Stock Options Under NASDAQ Listing Rule 5635(c)(4)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that on April 15, 2014, it approved the grant of stock options to 17 new employees to purchase an aggregate of 81,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Pacira, as permitted under NASDAQ Listing Rule 5635(c)(4). Pacira granted to 17 new ... 
Printer Friendly Version
04/08/14Pacira Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 8, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the pricing of its previously announced public offering of 1,600,000 shares of its common stock at a public offering price of $64.00 per share. After deducting underwriting discounts and commissions and estimated offering expenses, Pacira will receive net proceeds of approximately $96.0 million in the offering. In addition, Pacira has granted the... 
Printer Friendly Version
04/07/14Pacira Pharmaceuticals Announces Proposed Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it is offering $100 million of its common stock in a proposed underwritten public offering. In addition, Pacira intends to grant the underwriters a 30-day option to purchase up to $15 million of additional shares of common stock. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may... 
Printer Friendly Version
04/07/14Pacira Pharmaceuticals Enters into Strategic Co-Production Partnership with Patheon to Create Additional EXPAREL Manufacturing Capacity
New Manufacturing Facility to Meet Future Demand Exceeding the Estimated $400 Million of Current Production Capacity PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced entering into a strategic co-production partnership with Patheon, the pharmaceutical services business owned by DPx Holdings B.V., to manufacture and package EXPAREL® (bupivacaine liposome injectable suspension) a... 
Printer Friendly Version
04/04/14EXPAREL Use in Femoral Nerve Block for Total Knee Arthroplasty Further Supported by Additional Data from Phase 3 Pivotal Study, sNDA Submission Planned for Second Quarter 2014
Data Presented at the 39th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine PARSIPPANY, N.J. & CHICAGO--(BUSINESS WIRE)--Apr. 4, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) to achieve a femoral nerve block in patients undergoing total knee arthroplasty. The Company ... 
Printer Friendly Version
03/31/14Pacira Pharmaceuticals, Inc. Announces FDA Approval of Additional Manufacturing Suite for EXPAREL
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 31, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL® (bupivacaine liposome injectable suspension). The suite is housed at the company’s Science Center Campus in San Diego, where EXPAREL is currently manufactured. “We believe the approval of an ... 
Printer Friendly Version
03/14/14Two New Studies Support Use of EXPAREL for Postsurgical Pain Management Following Total Joint Replacement
Data Presented at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons Show EXPAREL Improved Pain Scores, Lowered Opioid Consumption, and Reduced Hospital Stays, Falls and Overall Costs PARSIPPANY, N.J. & NEW ORLEANS--(BUSINESS WIRE)--Mar. 14, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain ... 
Printer Friendly Version
03/06/14Pacira Pharmaceuticals Inc. Appoints Industry Expert Yvonne Greenstreet to its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Yvonne Greenstreet, MBChB, MBA, to its board of directors. “We are delighted to have Yvonne join as our newest board member,” said Dave Stack, president, chief executive officer and chairman of Pacira. “We believe that her vast experience working across a diverse range of critical functions at some of the most est... 
Printer Friendly Version
03/05/14Pacira Pharmaceuticals Announces EXPAREL® Data Presentations at 2014 Annual Meeting of the American Academy of Orthopedic Surgeons
Studies Assess Impact of EXPAREL on Postsurgical Pain and Health Economic Outcomes Following Total Knee and Hip Replacement Procedures PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that data evaluating the use of EXPAREL® (bupivacaine liposome injectable suspension) to manage postsurgical pain following knee and hip arthroplasty (replacement) procedures will be presented at... 
Printer Friendly Version
02/27/14Pacira Pharmaceuticals, Inc. Announces EXPAREL Phase 3 Clinical Trial in Femoral Nerve Block Meets Primary Efficacy Endpoint
sNDA Submission Expected in Second Quarter of 2014 with a 10-month PDUFA Timeline PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint. This pivotal Phase 3 trial eval... 
Printer Friendly Version
02/26/14Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 26, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014, at 9 a.m. ET in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be acc... 
Printer Friendly Version
02/25/14Pacira Pharmaceuticals, Inc. Reports 2013 Financial Results: Fourth Quarter EXPAREL Revenues Increase 53 Percent Over Third Quarter
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the fourth quarter and full year ended December 31, 2013. “We are very pleased with the overall performance and trajectory that we have seen in the ma... 
Printer Friendly Version
02/25/14Pacira Pharmaceuticals, Inc. Webcast Replay of 2013 Financial Results Conference Call
PARSIPPANY, N.J., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced that a replay of the company's fourth quarter and full-year 2013 financial results conference call, which took place today on Tuesday, February 25, 2014, at 9 a.m. ET, can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international), and providing the Conference ID 16366107. The replay of the call will be available for two weeks from the date of the live call. The... 
Printer Friendly Version
02/11/14Pacira Pharmaceuticals, Inc. Announces Timing for 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 11, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013, will be released before the market opens on Tuesday, February 25, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, February 25, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-07... 
Printer Friendly Version
01/29/14Data Update Supports Infiltration with EXPAREL® into the Transversus Abdominis Plane for Postsurgical Pain Management
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 29, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced key findings supporting the use of EXPAREL® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane (or iTAP) for postsurgical pain management. A recent independent study led by Andras Sandor, M.D., FACS, FASMBS, chairman of the Department of Surgery and director of the Hallmark H... 
Printer Friendly Version
01/07/14Phase 4 IMPROVE Publication Finds EXPAREL®- Based Multimodal Analgesia Reduces Opioid Use, Adverse Events and Hospital Stay Following Laparoscopic Surgery
-- Results Reinforce Findings from IMPROVE Trial Series Demonstrating the Opioid-Sparing and Economic Benefits of EXPAREL Compared to Standard Opioid-Based Regimen -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 7, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences ... 
Printer Friendly Version
12/05/13Pacira Pharmaceuticals, Inc. Announces Submission of Prior Approval Supplement for Additional EXPAREL® Manufacturing Suite
Anticipated PDUFA Date in Early April 2014 PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 5, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has submitted a Prior Approval Supplement (PAS) with the U.S. Food and Drug Administration (FDA) for an additional bulk manufacturing suite for EXPAREL® (bupivacaine liposome injectable suspension). Under the reauthorization of the Prescription Drug User Fee Act (PDUFA), the FDA establi... 
Printer Friendly Version
11/25/13Pacira Pharmaceuticals, Inc. to Present at the 25th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 25, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013, at 12:30 p.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacir... 
Printer Friendly Version
11/01/13Pacira Pharmaceuticals, Inc. to Present at November Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at investor conferences during November. Mr. Stack will present at the Goldman Sachs US Emerging / SMID Cap Growth Conference on Thursday, November 14, 2013, at 2:40 p.m. ET in ... 
Printer Friendly Version
10/31/13Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL® Revenue of $20.0 Million and Full Third Quarter 2013 Financial Results
Company Will Host Conference Call Today at 9:00 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 31, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the quarter ended September 30, 2013. “The strong third quarter for EXPAREL sales wa... 
Printer Friendly Version
10/17/13Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 17, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2013, will be released before the market opens on Thursday, October 31, 2013. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, October 31, 2013, at 9 a.m. ET. The call... 
Printer Friendly Version
10/01/13Pacira Pharmaceuticals, Inc. Announces Partnership to Support Uptake of EXPAREL® Among the Orthopedic Marketplace
Five-year arrangement with CrossLink Bioscience, LLC follows initial pilot program PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the initiation of a five-year promotion arrangement with CrossLink Bioscience, LLC, an orthopedic device distributor based in Atlanta. Under the agreement, CrossLink will act as a local agent as well as a lead partner in current collaboration with... 
Printer Friendly Version
09/19/13Study Shows EXPAREL® Provided Improved Pain Control, Shorter Length of Hospital Stay and Substantial Cost Savings Following Total Knee Replacement
Data Presented at 7th Annual Marshall Steele Orthopedic & Spine Summit PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 19, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results from a 200-patient study evaluating the benefits of EXPAREL® (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain management regimen in patients undergoing total knee arthroplasty (TKA), commonly known a... 
Printer Friendly Version
09/12/13Pacira Pharmaceuticals, Inc. Announces Appointment of Life Sciences Industry Veterans Mark Kronenfeld, M.D., and Dennis Winger to its Board of Directors
Company Founders and Venture Investors Fred Middleton and Luke Evnin to Retire from the Board PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 12, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark A. Kronenfeld, M.D., and Dennis L. Winger to its Board of Directors. Pacira also announced today that Luke Evnin, a managing director at MPM Capital, and Fred Middleton, a general manager at Sanderling Ve... 
Printer Friendly Version
08/06/13Pacira Pharmaceuticals, Inc. Reports Second Quarter EXPAREL® Revenue of $15.2 Million and Full Second Quarter 2013 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 6, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on the commercial success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the quarter ended June 30, 2013. “The second quarter marks the commencement of the secon... 
Printer Friendly Version
08/06/13Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 6, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2013 Life Sciences Management Access Conference on Tuesday, August 13, 2013, at 9:45 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
08/01/13EXPAREL Phase 3 Clinical Trial in Intercostal Nerve Block Does Not Meet Primary Endpoint
Based upon Ongoing Femoral Nerve Block Trial, sNDA Submission Still Planned for Early 2014 PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in intercostal nerve block for posterolateral thoracotomy. The study did not achieve its pri... 
Printer Friendly Version
07/30/13Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 30, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2013, will be released before the market opens on Tuesday, August 6, 2013. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, August 6, 2013, at 9 a.m. ET. The call can be ac... 
Printer Friendly Version
07/18/13New Study Shows Significant Reduction in Opioids, Length of Hospital Stay and Cost of Care for Patients Receiving EXPAREL® as the Foundation of a Multimodal Postsurgical Pain Regimen
Multicenter study in patients undergoing ileostomy reversal reinforces results from first IMPROVE study in open colectomy PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 18, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results from the second IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal of Pain Research. The IMPROVE studies assess the differences in ... 
Printer Friendly Version
05/29/13Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty
Completed Dose Ranging Portion of Pivotal Nerve Block Trial; Phase 3 Initiating; sNDA on Track for Early 2014 PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 29, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL® (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block ... 
Printer Friendly Version
05/28/13Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2013 Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 28, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Monday, June 3, 2013, at 10:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be acce... 
Printer Friendly Version
05/08/13Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 8, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that James Scibetta, chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 5:00 p.m. PT at the Encore at the Wynn in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio webc... 
Printer Friendly Version
05/08/13Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL Revenue and Full First Quarter 2013 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 8, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the quarter ended March 31, 2013 and provided updates on the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States. “We saw a solid quarter in what was the fourth quarter ... 
Printer Friendly Version
05/06/13Two New Studies Support Use of EXPAREL via Infiltration Into the Transversus Abdominis Plane for Postsurgical Pain Control
Data Presented at Annual Meetings of Leading Regional Anesthesia Societies Demonstrate Analgesia for Up to 72 Hours and High Patient Satisfaction PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 6, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced findings from two new studies supporting the use of EXPAREL® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane for postsurgical pain managem... 
Printer Friendly Version
05/01/13Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 1, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2013, will be released before the market opens on Wednesday, May 8, 2013. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, May 8, 2013, at 9 a.m. ET. The call can be acces... 
Printer Friendly Version
04/25/13New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality
Retrospective Study Published in Pharmacotherapy Identifies Advanced Age, Obesity, Pre-Surgery Opioid Use and Comorbid Conditions as Predictive Risk Factors for Adverse Events PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 25, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital h... 
Printer Friendly Version
04/12/13New Data Support the Benefits of EXPAREL for Postsurgical Analgesia Following Aesthetic Plastic Surgery Procedures
Results Presented at American Society for Aesthetic Plastic Surgery Meeting Show Patients Treated with EXPAREL Reported Low Pain Scores, High Satisfaction and Minimal Opioid Use NEW YORK--(BUSINESS WIRE)--Apr. 12, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from EXCLAIM, its Phase 4 prospective, observational study to assess the use of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical ... 
Printer Friendly Version
04/05/13Pacira Pharmaceuticals, Inc. to Close The NASDAQ Stock Market on April 8, 2013
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 5, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, will close The NASDAQ Stock Market on Monday, April 8, 2013, in celebration of the one-year anniversary of the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension). Members of the Pacira team will join Mr. Stack at the ceremony at the N... 
Printer Friendly Version
03/27/13Analysis of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost and Higher Likelihood of Readmission
Retrospective Study Published in Journal of Pain and Palliative Care Pharmacotherapy Utilized National Hospital Database and Assessed Nearly 320,000 Surgeries PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 27, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data from a large-scale analysis of a national database of patients from 380 hospitals in the United States who underwent 319,898 inpatient surgeries and received opioids... 
Printer Friendly Version
03/07/13Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated 2012 financial results and provided updates on the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States. "The launch of EXPAREL continues to go well. Weekly growth in new customers and continued expansion in hospitals that have gained experience with the product support our belief that EXPAREL provides a significant opportun... 
Printer Friendly Version
03/06/13Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013, at 2:30 p.m. ET at the Loews Hotel in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira... 
Printer Friendly Version
02/28/13Pacira Pharmaceuticals, Inc. Announces Timing for 2012 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 28, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012, will be released before the market opens on Thursday, March 7, 2013. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, March 7, 2013, at 9 a.m. ET. T... 
Printer Friendly Version
02/25/13Pacira Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 25, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013, at 4:10 p.m. ET at the Boston Marriott Copley Place in Boston. Mr. Stack is expected to present an overview of the company. A li... 
Printer Friendly Version
01/17/13Pacira Pharmaceuticals, Inc. Announces Pricing of $110 Million Private Offering of Convertible Senior Notes
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 17, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) (the “Company”) today announced that it has priced its private offering of $110 million in aggregate principal amount of its 3.25 percent Convertible Senior Notes due 2019. The Company has also granted the initial purchasers a 30-day option to purchase up to an additional $10 million in aggregate principal amount of the notes on the same terms and co... 
Printer Friendly Version
01/15/13Pacira Pharmaceuticals, Inc. Announces Proposed Offering of $100 Million of Convertible Senior Notes
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 15, 2013-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) (the “Company”) today announced that it proposes to offer $100 million of aggregate principal amount of its convertible senior notes due 2019, subject to market conditions and other factors. The notes are to be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The notes will be... 
Printer Friendly Version
12/18/12New Publication Suggests Higher Opioid Use in the Postsurgical Setting May Be Linked to Extended Hospital Stay and Increased Cost of Care
PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 18, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that the full findings from the regional health system analysis conducted by Barnabas Health to quantify the relationship between opioid use, total hospital charges and patient length of stay (LOS) were published in Hospital Pharmacy. This study demonstrated that in addition to increased hospital charges, patients undergoing total abd... 
Printer Friendly Version
12/06/12Pacira Pharmaceuticals, Inc. and Aratana Therapeutics Inc. Enter into Global Licensing Agreement for Development and Commercialization of Bupivacaine Liposome Injectable Suspension for Animal Health Indications
PARSIPPANY, N.J. & KANSAS CITY, Kan.--(BUSINESS WIRE)--Dec. 6, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Aratana Therapeutics Inc. today announced a global licensing agreement for the development and commercialization of bupivacaine liposome injectable suspension for animal health indications. Under the agreement, Aratana will develop and seek approval for the use of the product in veterinary surgery to manage postsurgical pai... 
Printer Friendly Version
11/20/12New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay with EXPAREL as the Foundation of a Multimodal Regimen
Results published in the Journal of Pain Research compare cost of care between standard opioid-based regimen and EXPAREL-based multimodal regimen for postsurgical pain management PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 20, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results from the first IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal ... 
Printer Friendly Version
11/20/12Pacira Pharmaceuticals, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 20, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference at The New York Palace Hotel on Tuesday, November 27, at 2 p.m. ET. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira pr... 
Printer Friendly Version
11/13/12New Data Supporting Use of EXPAREL via Infiltration into the Transversus Abdominis Plane Presented at 11th Annual American Society of Regional Anesthesia and Pain Medicine Meeting
Survey Demonstrating Continued Under-Management of Postsurgical Pain Also Presented PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 13, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the first data presentation supporting the use of EXPAREL® (bupivacaine liposome injectable suspension) infiltrated into the transversus abdominis plane (TAP) for postsurgical pain management. TAP infiltration is being increasingly utili... 
Printer Friendly Version
11/08/12Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Presentation to be Webcast at 9:20 a.m. GMT on Thursday, November 15 PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 8, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2012 Global Healthcare Conference in London on Thursday, November 15 at 9:20 a.m. GMT (4:20 a.m. ET). Mr. Stack is expected to present a... 
Printer Friendly Version
11/01/12Pacira Pharmaceuticals, Inc. Reports $4.6 Million in Third Quarter EXPAREL® Revenue and Full Third Quarter 2012 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 1, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the quarter ended September 30, 2012 and provided updates on the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States. “We launched EXPAREL in April and have suc... 
Printer Friendly Version
10/25/12Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 25, 2012-- Pacira Pharmaceuticals, Inc (NASDAQ: PCRX) today announced that financial results for the company's third quarter ended September 30, 2012, will be released before the market opens on Thursday, November 1, 2012. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, November 1, 2012, at 9 a.m. ET. The ... 
Printer Friendly Version
10/18/12Richard A. Baxter, M.D., Receives OR Excellence Award for Use of EXPAREL®
Award recognizes plastic surgeon for "Best Use of Opioid Alternatives" PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 18, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that prominent Seattle-based plastic surgeon Richard A. Baxter, M.D., FACS was recognized by Outpatient Surgery magazine for his use of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain management. The award for "Best Use of Opioid Alternatives" will be presented during the OR Excellence C... 
Printer Friendly Version
10/08/12EXPAREL® as the Foundation of a Multimodal Regimen Achieves Statistical Significance in All Primary Endpoints, Including a 60 Percent Reduction in Length of Hospital Stay
IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 8, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced topline results from the first completed IMPROVE study in its prospective Phase 4 clinical program. The study was designed to compare the difference in three primary end... 
Printer Friendly Version
09/25/12Pacira Pharmaceuticals, Inc. Launches EXPAREL® Pivotal Nerve Block Trial
First patient enrolled in two-part study to assess the safety and efficacy of EXPAREL in femoral nerve block PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced initiation of its Phase 2/3 pivotal trial of EXPAREL® (bupivacaine liposome injectable suspension) administered as a single-dose injection femoral nerve block for total knee arthroplasty surgery. Results ... 
Printer Friendly Version
09/12/12Pacira Pharmaceuticals, Inc. to Present at the UBS Global Life Sciences Conference
Presentation to be Webcast at 4:30 pm ET on Wednesday, September 19th PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 12, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Wednesday, September 19 at 4:30 p.m. ET. Mr. Stack is expected to present an ... 
Printer Friendly Version
09/05/12Reduced Pain, Opioid Use, and Opioid-Related Adverse Events in Patients Receiving EXPAREL® Compared With Patients Receiving Bupivacaine HCl as a Component of Multimodal Therapy
Results from Pooled Analysis of More than 900 Patients Published Online in Current Medical Research and Opinion PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 5, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the publication of results from a pooled analysis of nine clinical trials across five surgical models that compared cumulative pain scores, opioid consumption and occurrence of opioid-related adverse events (ORAEs) fo... 
Printer Friendly Version
08/09/12Pacira Pharmaceuticals, Inc. Reports $2.3 Million in Second Quarter EXPAREL® Revenue and Full Second Quarter 2012 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 9, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the quarter ended June 30, 2012 and provided updates on the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States. “With our first quarter of EXPAREL sales behind... 
Printer Friendly Version
08/07/12Pacira Pharmaceuticals, Inc. to Present at the Wedbush PacGrow 2012 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 7, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Wedbush PacGrow 2012 Life Sciences Management Access Conference on Tuesday, August 14, 2012, at 8:35 a.m. ET at Le Parker Meridien in New York. Mr. Stack is expected to present an overview of the company. A l... 
Printer Friendly Version
07/31/12Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2012 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company's second quarter ended June 30, 2012, will be released before the market opens on Thursday, August 9, 2012. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, August 9, 2012, at 9 a.m. ET. The call ca... 
Printer Friendly Version
06/05/12New Data Quantifying the Effects of Opioid Use on Patient Care and Economic Outcomes Presented at Key Medical Meetings
Impact of Opioid-Related Adverse Drug Events on Total Hospital Cost Presented at American Society of Colon and Rectal Surgeons (ASCRS) Meeting Impact of Opioid Use and Ileus Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 5, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data that demonstrate opioid-relat... 
Printer Friendly Version
05/29/12Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 29, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Monday, June 4, 2012, at 10:00 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be... 
Printer Friendly Version
05/21/12Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 21, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index® (NASDAQ: NBI) effective today. The National Biotechnology Index is designed to track the performance of biotechnology or pharmaceutical companies listed exclusively on the NASDAQ Global Select Market or on the NASDAQ Global Market that meet eligibility criteria... 
Printer Friendly Version
05/10/12Pacira Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2012 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 10, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that James Scibetta, chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17, 2012, at 10:40 a.m. PT at The Encore at Wynn in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio web... 
Printer Friendly Version
05/09/12Pacira Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 9, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the quarter ended March 31, 2012 and reviewed recent accomplishments, including the commercial launch in the United States of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain and the successful completion of an equ... 
Printer Friendly Version
05/03/12Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing
Terms Defer Principal Repayment and Lock In Lower Interest Rate PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 3, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has secured a $27.5 million debt financing facility through Oxford Finance. Pacira will use the proceeds from this financing to refinance the remaining principal of its outstanding term loan and for general corporate purposes. The refinancing allows Pacira t... 
Printer Friendly Version
05/02/12Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2012 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 2, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company's first quarter ended March 31, 2012, will be released before the market opens on Wednesday, May 9, 2012. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Wednesday, May 9, 2012, at 9 a.m. ET. The call can be ... 
Printer Friendly Version
04/25/12Pacira Pharmaceuticals, Inc. Announces Full Exercise of Overallotment Option by Underwriters
PARSIPPANY, N.J., Apr 25, 2012 (BUSINESS WIRE) --Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their overallotment option to purchase an additional 900,000 shares of common stock at the public offering price of $9.75 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximate... 
Printer Friendly Version
04/12/12Pacira Pharmaceuticals, Inc. Prices Public Offering of Common Stock
PARSIPPANY, N.J., Apr 12, 2012 (BUSINESS WIRE) --Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $9.75 per share to the public. All of the shares are being sold by Pacira. The gross proceeds to Pacira from this offering are expected to be approximately $58.5 million, before deducting underwriting discounts and commissions, and other estimated of... 
Printer Friendly Version
04/11/12Pacira Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 11, 2012-- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Pacira. Jefferies & Company, Inc. and Barclays Capital Inc. are acting as joint book-running managers for the offering. Piper Jaffray & Co., Wedbush PacGrow Life Sciences and Brean Mu... 
Printer Friendly Version
04/09/12Pacira Pharmaceuticals, Inc. Announces Commercial Availability of EXPAREL®
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 9, 2012-- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) in the United States. Starting today, EXPAREL will begin shipping to hospital and ambulatory care customers through their normal wholesaler and distributor channels. EXPAREL was approved by the U.S. Food and Drug Administration (FDA) in October 2011 f... 
Printer Friendly Version
03/27/12Pacira Pharmaceuticals, Inc. Reports 2011 Financial Results
Company On Track for Commercial Launch of EXPAREL® in April PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 27, 2012-- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced consolidated 2011 financial results, reviewed key 2011 accomplishments and reiterated that it expects to initiate the commercial launch of EXPAREL® (bupivacaine liposome injectable suspension) in the U.S. the week of April 9. EXPAREL was approved by the U.S. Fo... 
Printer Friendly Version
03/20/12Pacira Pharmaceuticals, Inc. Announces Timing for 2011 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 20, 2012-- Pacira Pharmaceuticals, Inc (Nasdaq: PCRX) today announced that financial results for the company's fourth quarter and year ended Dec. 31, 2011, will be released before the market opens on Tuesday, March 27, 2012. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Tuesday, March 27, 2012, at 9 a.m. ET. The c... 
Printer Friendly Version
03/07/12Pacira Pharmaceuticals, Inc. to Present at Barclays Capital Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 7, 2012-- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2012, at 4:45 p.m. ET at the Loews Hotel in Miami Beach. Mr. Stack is expected to present an overview of the company. A live audio webcast... 
Printer Friendly Version
02/21/12Pacira Pharmaceuticals, Inc. to Participate in RBC Capital Markets Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 21, 2012-- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to participate in a panel titled “New Developments in Neurology” at the RBC Capital Markets Global Healthcare Conference on Tuesday, Feb. 28, 2012, at 2:35 p.m. EST at the New York Palace Hotel & Conference Center in New York City. ... 
Printer Friendly Version
01/09/12Pacira Pharmaceuticals, Inc. Provides Update on Commercial Launch and Product Availability Timing for EXPAREL®
EXPAREL Expected to be Commercially Available in April 2012 PARSIPPANY, N.J., Jan 09, 2012 (BUSINESS WIRE) --Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updated timing for its commercial launch of EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia. Since FDA approval of EXPAREL in October 2011, Pacira has cont... 
Printer Friendly Version
12/19/11Pacira Pharmaceuticals, Inc. Announces Results from EXPAREL™ Pivotal Trial Published in Diseases of the Colon & Rectum
Data Demonstrate Significant Reduction in Cumulative Pain Scores and Opioid Use with EXPAREL in Soft Tissue Surgical Model PARSIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL™ (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for admini... 
Printer Friendly Version
12/05/11New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
Research Utilizing National and Regional Health System Databases Presented PARSIPPANY, N.J., Dec. 5, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced new data gleaned from a national database of patients from 381 U.S. hospitals who underwent common hospital-based surgical procedures and received opioids for postsurgical pain management. The data demonstrate that opioid-related adverse events (ORAEs) are associated with more than a $1,000 increase ... 
Printer Friendly Version
11/22/11Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option
PARSIPPANY, N.J., Nov. 22, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced it has completed a follow-on offering of 7,000,000 shares of its common stock, at a price to the public of $6.50 per share. Pacira also announced that its underwriters have exercised their over-allotment option in full to purchase an additional 1,050,000 shares of common stock, also at $6.50 per share. All of the 8,050,000 shares a... 
Printer Friendly Version
11/16/11Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share. All of the 7,000,000 shares are newly issued and are being offered by Pacira, with expected net proceeds to Pacira of approximately $42.3 million after deducting underwriting discounts and commissions and estimated offering expenses. I... 
Printer Friendly Version
10/31/11Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
Company Provides Update on FDA Approval of EXPAREL™ and Commercial Strategy PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL™ (bupivacaine liposome injectable suspension) and the commercial strategy to support the product l... 
Printer Friendly Version
10/31/11Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL™ For Postsurgical Pain Management
Company Will Host Conference Call Today, Oct. 31, 2011, to Discuss FDA Approval and Third Quarter Financial Results PARSIPPANY, N.J., Oct. 31, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) announces that the U.S. Food and Drug Administration (FDA) has approved EXPAREL™ (bupivacaine liposome injectable suspension) 1.3% for administration into the surgical site to produce postsurgical analgesia. In a pivotal hemorrhoidectomy trial of EXPAREL compared to placebo, wh... 
Printer Friendly Version
10/24/11Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 24, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that financial results for the company's third quarter ended September 30, 2011 will be released before the market opens on Monday, Oct. 31, 2011. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Monday, Oct. 31, 2011 at 9 a.m. ET. The call can... 
Printer Friendly Version
10/19/11Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
Pooled Analysis Findings Presented at American College of Clinical Pharmacy Annual Meeting; Data Demonstrating Sustained-Release Properties of EXPAREL also Presented PARSIPPANY, N.J., Oct. 19, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced new data demonstrating a reduction in opioid burdens with EXPAREL™ (bupivacaine liposome extended-release injectable suspension) at doses up to and including 300 mg compared to bupivacaine HCl in a multimodal set... 
Printer Friendly Version
10/18/11Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
PARSIPPANY, N.J., Oct. 18, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that new data discussing the pharmacoeconomic impact of EXPAREL™ (bupivacaine liposome extended-release injectable suspension), the company's lead investigational product for postsurgical pain management, will be presented during a podium presentation at the American College of Surgeons (ACS) 97th Annual Clinical Congress in San Francisco on Wednesday, October 26. Another podiu... 
Printer Friendly Version
10/11/11Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
PARSIPPANY, N.J., Oct. 11, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that new data highlighting the pain control and pharmacokinetic properties of EXPAREL™ (bupivacaine liposome extended-release injectable suspension), the company's lead investigational product for postsurgical pain management, will be presented during poster presentations at the 2011 Annual Meetings of the American Society of Anesthesiologists (ASA) and the American College of ... 
Printer Friendly Version
09/26/11Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
Data From Two-Year Follow-up Study Assessing EXPAREL Safety in Breast Augmentation Surgery Using Silicone Implant Also Presented DENVER and PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) today announced that the company's lead investigational product for postsurgical pain management, EXPAREL™ (bupivacaine liposome extended-release injectable suspension), was highlighted in the "Hot Topics in Plastic Surgery" panel at the annual scientif... 
Printer Friendly Version
09/13/11Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
PARSIPPANY, N.J., Sept. 13, 2011 /PRNewswire via COMTEX/ --Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011, at 11 a.m. EDT to be held at the Grand Hyatt New York Hotel & Conference Center in New York City. Mr. Stack is expected to present an overview of th... 
Printer Friendly Version
09/06/11Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
Agreements with Leading Marketing and Logistics Firms to Support Anticipated EXPAREL Launch PARSIPPANY, N.J., Sept. 6, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that it has entered into agreements with Quintiles Commercial US, Inc. (Quintiles) and Integrated Commercialization Services, Inc. (ICS) to support the anticipated launch of EXPAREL™ (bupivacaine liposome extended-release injectable suspen... 
Printer Friendly Version
08/12/11Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
PARSIPPANY, N.J., Aug. 12, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Wedbush Securities 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011, at 10:35 a.m. EDT being held at the Le Parker Meridien Hotel & Conference Center in New York City. Mr. Stack is expected... 
Printer Friendly Version
08/11/11Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
Continued Execution of Pre-Commercial Strategy Company Updates Fourth Quarter "Cash Burn" Guidance Based Upon Revised FDA Timeline PARSIPPANY, N.J., Aug. 11, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL™, and updated its 2011 financial guidance. ... 
Printer Friendly Version
08/02/11Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
Data Demonstrate the Safety of DepoFoam®; Key Delivery Technology Used in EXPAREL™ PARSIPPANY, N.J., Aug. 2, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that new preclinical data evaluating the safety of DepoFoam® with DEPC (a novel excipient) will be presented in two podium sessions at the 38th Annual Meeting & Exposition of the Controlled Release Society (CRS) in National Harbor, Md. DepoFoam ... 
Printer Friendly Version
07/28/11Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., July 28, 2011 /PRNewswire via COMTEX/ --Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that financial results for the company's second quarter ended June 30, 2011 will be released before the market opens on Thursday, Aug. 11, 2011. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, Aug. 11, 2011 at 9 a.m. ET. The call can b... 
Printer Friendly Version
06/27/11Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
PARSIPPANY, N.J., June 27, 2011 /PRNewswire via COMTEX/ --Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that it has been included in the Russell 3000® Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global equity indexes on June 24, 2011. The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies representing approximately 98 percent of the investable U.S. equity m... 
Printer Friendly Version
06/14/11Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
PARSIPPANY, N.J., June 14, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for EXPAREL™ (Bupivacaine Extended-Release Liposome Injection) by three months. The new PDUFA goal date is October 28, 2011. The FDA requested additional informatio... 
Printer Friendly Version
06/02/11Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
Laura A. Brege and Paul J. Hastings bring more than 50 years of financial, operational and commercial expertise to the board PARSIPPANY, N.J., June 2, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company, today announced the appointments of Laura A. Brege and Paul J. Hastings to its board of directors. Together, Brege and Hastings bring more than five decades of biotechnology and pharmaceutical industry experience with both ... 
Printer Friendly Version
05/24/11Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
PARSIPPANY, N.J., May 24, 2011 /PRNewswire via COMTEX/ --Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that Gary Patou, M.D., chief medical officer, is scheduled to present at the UBS Global Specialty Pharmaceuticals Conference being held in London on Wednesday, May 25, 2011 at noon BST. Dr. Patou is expected to present an overview of the company. A live audio webcast of Pacira's presentation can be accessed by visiting the invest... 
Printer Friendly Version
05/23/11Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
Data Highlights Safety, Efficacy for EXPAREL across Multiple Surgical Models PARSIPPANY, N.J., May 23, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that clinical data highlighting the safety profile of EXPAREL™ (bupivacaine extended-release liposome injection) will be presented at the 2011 International Anesthesia Research Society (IARS) Annual Meeting in Vancouver, British Columbia. Comprehensi... 
Printer Friendly Version
05/16/11Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
Data Demonstrate the Utility of EXPAREL in Reducing Pain and Opioid Use for 72 Hours Following Hemorrhoidectomy Surgery PARSIPPANY, N.J., May 16, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL™ in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeti... 
Printer Friendly Version
05/11/11Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
Continued Progress in EXPAREL Health Economics and Education Programs PARSIPPANY, N.J., May 11, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL™, and reiterated 2011 financial guidance. "During the first quarter we have continued to work closely w... 
Printer Friendly Version
05/05/11Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
-- New Phase 3 Data to be Presented at the Society for Ambulatory Anesthesia (SAMBA) 26th Annual Meeting Demonstrate the Utility of EXPAREL In Breast Augmentation Surgery -- -- Preclinical and Phase 1 Clinical Data to be Presented at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 36th Annual Regional Anesthesia Meeting and Workshops Highlight the Safety and Tolerability of EXPAREL -- PARSIPPANY, N.J., May 5, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (... 
Printer Friendly Version
05/04/11Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., May 4, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that financial results for the company's first quarter ended March 31, 2011 will be released before the market opens on Wednesday, May 11, 2011. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Wednesday, May 11, 2011 at 10 a.m. EDT. The call can... 
Printer Friendly Version
04/08/11Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
PARSIPPANY, N.J., April 8, 2011 /PRNewswire via COMTEX/ --Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company, today announced James Scibetta, chief financial officer, is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 15, 2011, at 11:30 a.m. EDT being held at the Millennium Broadway Hotel & Conference Center in New York City. Mr. Scibetta is expected to present an overview of the company. A ... 
Printer Friendly Version
03/31/11Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
Continued Progress in Pre-Commercial Activities; 2011 Financial Guidance Established PARSIPPANY, N.J., March 31, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the fourth quarter and full-year ended December 31, 2010, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL™ and established 2011 financial guidance. "Since our initial public ... 
Printer Friendly Version
03/24/11Pacira Pharmaceuticals Announces Timing for 2010 Financial Results, Webcast and Conference Call
PARSIPPANY, N.J., March 24, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that financial results for the company's fourth quarter and year ended December 31, 2010 will be released before the market opens on Thursday, March 31, 2011. The Pacira management team will host a conference call discussing the company's financial results and recent and upcoming developments on Thursday, March 31, 2011 at 9:00 a.m... 
Printer Friendly Version
03/08/11Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
PARSIPPANY, N.J., March 8, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that David Stack, president and chief executive officer, is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011, at 9:30 a.m. EDT being held at the Loews Miami Hotel in Miami, FL. Mr. Stack is expected to present an overview of the company. A live audio webcast of Pacira's pre... 
Printer Friendly Version
03/02/11Pacira Pharmaceuticals' EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
SAN DIEGO and PARSIPPANY, N.J., March 2, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that positive results from its Phase 1 study evaluating EXPAREL™ (bupivacaine extended-release liposome injection) in patients with moderate hepatic impairment, will be presented at the 2011 American Society for Clinical Pharmacology and Therapeutics (ASCPT) 112th Annual Meeting in Dallas, TX. Results from this Phase... 
Printer Friendly Version
02/15/11Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
EXPAREL Well Tolerated and Did Not Adversely Impact Wound Healing; Poster Selected as Meeting's Best in 'Foot and Ankle' Category SAN DIEGO, and PARSIPPANY, N.J., Feb. 15, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that additional safety data are being highlighted from its Phase 3 trial of EXPAREL™ (bupivacaine extended-release liposome injection) in bunionectomy. The data showed comparable s... 
Printer Friendly Version
02/03/11Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
PARSIPPANY, N.J., Feb. 3, 2011 /PRNewswire via COMTEX/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Pacira. The shares are expected to begin trading on the NASDAQ Global Market under the symbol "PCRX" on February 3, 2011. In addition, Pacir... 
Printer Friendly Version
01/13/11Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society’s 57th Annual Meeting
Data Demonstrates that Patients Treated with EXPAREL Were Able to Forgo Opioid Rescue Medications for a Longer Time Period Following Surgery than Patients Treated with Placebo Parsippany, NJ – January 13, 2011 - Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that new data from its Phase 3 bunionectomy study to evaluate the efficacy and safety of the intraoperative administration of EXPAREL™ (bupivacaine extended-release liposome injection) is being p... 
Printer Friendly Version
12/14/10Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
Parsippany, NJ - December 14, 2010 - Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, announced today that the New Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for postsurgical pain management, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Pacira submitted the EXPAREL NDA in September 2010 for the initial indication of postsurgical analgesia by local administration. The FDA also notified Pacira that its Prescription Drug... 
Printer Friendly Version
12/01/09Pacira Announces Results of Another Positive Phase III Trial in Post Operative Pain
EXPAREL™ achieves primary endpoint in hemorrhoidectomy trial Parsippany, NJ - December 1, 2009 - Pacira Pharmaceuticals, Inc., announced today that its second Phase III placebo controlled study of EXPAREL™ (DepoBupivacaine) met its primary endpoint. The multicenter, randomized, double-blind, parallel group, placebo controlled study in hemorrhoidectomy showed a statistically significant reduction in area under the curve analysis (AUC) of the NRS pain scores in patients receiving EXPAREL™ comp... 
Printer Friendly Version
10/20/09Pacira's Phase III Study of EXPAREL™ Meets Primary Pain Relief Endpoint
Parsippany, NJ, October 20, 2009 - Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that its Phase III study of its new analgesic EXPAREL™ (DepoBupivacaine) in patients undergoing a bunionectomy procedure met its primary endpoint. The multicenter, randomized, double-blind, parallel-group, placebo controlled study showed a statistically significant reduction in area under the curve analysis (AUC) of the NRS scores in the subjects receiving EXPAREL™ com... 
Printer Friendly Version
01/06/09Phase III Studies of EXPAREL™ (DepoBupivacaine) from Pacira Complete Enrollment
Data from Soft Tissue and Bone Surgery Studies Basis of Planned 2009 NDA Filing Parsippany, NJ, January 6, 2009 - Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that enrollment has been completed in two pivotal Phase III SIMPLE trials to evaluate the safety and efficacy of a single intraoperative administration of EXPAREL™ (DepoBupivacaine) for prolonged postoperative analgesia. Results from the studies in hemorrhoidectomy and in total knee arthr... 
Printer Friendly Version
12/14/08Positive Phase II Study of Pacira’s EXPAREL™ (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
Novel Local Analgesic Results in Sustained Plasma Concentrations Significantly Reducing Postoperative Pain Parsippany, NJ, Dec. 14, 2008 - A Phase II trial of a single intraoperative administration of EXPAREL (DepoBupivacaine) resulted in significantly reduced pain with activity in the first 8 to 24 hours following surgery, when pain is generally greatest, compared to conventional treatment. The results of the multicenter, randomized, double-blind study were presented in a poster at the Annua... 
Printer Friendly Version
12/06/08Positive Phase II Study of Pacira's EXPAREL™ (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
New Sustained-Release Analgesic Significantly Reduces Postop Pain, Opioid Use, and Reduces Opioid Related Adverse Events Compared to Gold Standard Pain Medication Parsippany, NJ, Dec. 6, 2008 - A Phase II dose escalation study of a single intraoperative administration of EXPAREL™ (DepoBupivacaine) in patients who underwent total knee arthroplasty, or TKA, showed that the novel, sustained-release analgesic effectively and safely controlled moderate-to-severe postoperative pain for over 72 hour... 
Printer Friendly Version
10/02/08Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
Parsippany, NJ, October 2, 2008 – Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company’s management team. David St. Peter, M.D. joins Pacira as Vice President of Medical Education and Scientific Affairs. Dr. St. Peter was previously with inVentiv Health where he held several senior management positions since 2001, most recently serving on their Executive Team as president of The Selva Group, LLC, a m... 
Printer Friendly Version
08/06/08Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
Parsippany, NJ, August 6 2008 - Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company's management team.  James S. Scibetta, joins Pacira as the Chief Financial Officer.  Mr. Scibetta brings more than 20 years of financial leadership experience in private and public companies as well as investment banking to Pacira.  Most recently he has been consulting to Genzyme Corporation (NASDAQ: GEN... 
Printer Friendly Version
07/08/08Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the appointment of a new Board member and the addition of a key senior executive to the company’s management team. Gary Pace, Ph.D, joins the Board of Directors as a seasoned biopharmaceutical executive with more than 30 years of experience. Dr. Pace brings his development and commercial experience to Pacira as the founder and past Chairman and CEO of QRx Pharma Ltd (ASX: QRX), as well as holding direct... 
Printer Friendly Version
04/15/08Pacira Pharmaceuticals, Inc. Expands Development Collaborations for Depofoam®
Pacira Pharmaceuticals, Inc. today announced a collaboration with Amylin Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam® technology platform from Pacira. The companies will work together to enhance the dosing profile for compounds within Amylin’s early research and development pipeline. The goal of the collaboration is to develop multiple products based on sustained release, subcutaneous injection. Dave Stack, President and CEO of Pacira... 
Printer Friendly Version
12/17/07Pacira Pharmaceuticals Names David M. Stack CEO and President
Pacira Pharmaceuticals, Inc., a leader in sustained release injectable technologies, today announced that David M. Stack has been selected as President, Chief Executive Office, and member of the Board of Directors. Mr. Stack is currently the CEO and founding partner of Stack Pharmaceuticals, Inc., a commercialization, marketing and strategy firm serving emerging healthcare companies. He also is an Executive Partner at MPM Capital. “David Stack is a proven, successful pharmaceutical executive w... 
Printer Friendly Version
10/22/07Orphan Australia Pty Ltd receives registration approval for the new dose form DepoDur®, Pacira’s modified release injection of morphine sulfate
Pacira Pharmaceuticals, Inc. today announced that Orphan Australia Pty Ltd, an Australian owned pharmaceutical company dedicated to providing novel, highly specialized pharmaceuticals, has been granted registration approval by the Therapeutic Goods Administration for DepoDur® in Australia. DepoDur, which was developed by and licensed from Pacira Pharmaceutical, Inc. and utilizes Pacira’s DepoFoam® technology, is a novel, single dose modified–release formulation of morphine. The approved indicat... 
Printer Friendly Version
09/27/07Flynn Pharma Acquires Rights from Pacira Pharmaceuticals to DepoDur®
Flynn Pharma Limited, a specialty pharmaceutical company focused on acquiring and commercializing proprietary products in secondary healthcare and related markets, today announced it has acquired exclusive marketing and distribution rights to DepoDur® (morphine sulphate extended release liposome injection) for Europe and a number of other markets from San Diego-based Pacira Pharmaceuticals. Pacira Pharmaceuticals, a former business unit of SkyePharma, PLC, is an independent private company focu... 
Printer Friendly Version
08/15/07EKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur®
EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing, and commercializing proprietary products to enhance patient quality-of-life in the acute care setting, today announced it has acquired exclusive marketing and distribution rights to DepoDur® (morphine sulfate extended release liposome injection) for the Americas from San Diego-based Pacira Pharmaceuticals who will continue to manufacture the product. Formerly a business unit of SkyePharma, PLC, Pacira P... 
Printer Friendly Version
06/22/07SkyePharma, Inc., Now a Private Pharmaceutical Company, Announces Name Change to Pacira Pharmaceuticals, Inc.
SkyePharma Inc. announced today that the company has changed its name to Pacira Pharmaceuticals, Inc. The name change reflects Pacira’s transformation from a former business unit of SkyePharma PLC to an independent, private company with existing commercial products, a strong product in clinical development, and novel drug delivery technologies for the sustained-release of injectable pharmaceutical products. Pacira, Inc. (formerly Blue Acquisition Corp.), which is now controlled and funded by a ... 
Printer Friendly Version
Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com